ActiPatch Therapy Shows Potential in Chronic Pain Relief

ActiPatch Therapy Shows Potential in Chronic Pain Relief
The chronic pain therapy ActiPatch, developed by BioElectronics Corp., has reached positive results in a seven-day trial evaluating its efficacy in chronic pain management. Results from the trial of the pulsed shortwave device have been released in a report entitled “A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy,” published in Pain Management. Management of chronic musculoskeletal pain often requires pharmacologic and nonpharmacologic therapies that have been shown to be ineffective, poorly tolerated, or inadequate in many individuals. Common causes for chronic pain include rheumatoid arthritis, osteoarthritis, injuries, and fibromyalgia. ActiPatch is an alternative, easy-to-use, low power, and noninvasive therapy device for musculoskeletal pain. It requires, the researchers noted, two basic requirements for use: activating the device through an on/off switch and affixing it via flexible circular wraps or medical tape to the body area causing pain. This therapy is already available over-the-counter in the U.K. and has been previously shown to reduce postoperative pain and need for pain medication in breast augmentation patients, as well as positive relief effects on plantar fasciitis and osteoarthritis of the knee. To evaluate its efficacy at a large scale, researchers conducted a seven-day trial equal to the number of days the device can maintain its battery power in continuous use, as recommended. The trial included responses from 5,002 patients of the 44,000 who received the ActiPatch device. Most participants suffered from chron
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *